Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Bladder Cancer Clinical Trial

Official title:

A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03520231
• Other study ID #: DENIM
• Status: Completed
• Phase: Phase 2
• Start date: September 4, 2018
• Est. completion date: December 1, 2020

Study information

• Verified date: September 2020
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer.

The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial cancer. This will be done by comparing denosumab with standard treatment, compared to placebo and standard treatment.

Denosumab is a monoclonal antibody that binds to a protein called Receptor Activator of Nuclear Factor κB (RANK). RANK works by telling certain cells called osteoclasts to break down bone tissue. The binding of denosumab to RANK stops it from telling osteoclasts to break down bone tissue which may help with symptoms related bone metastases from urothelial cancer.

Description:

This is a multicenter, randomized, double blind, Phase II study. Participants eligible for this study have metastatic urothelial cancer and bone metastases and are planned to receive 4-6 cycles of a standard of care platinum-doublet regimen. In a double blind manner, 50 participants will be randomized in a 1:1 ratio to receive denosumab 120 mg or matching placebo subcutaneously every 4 weeks with their first dose coinciding with the first cycle of chemotherapy. Patients will continue on denosumab/placebo even after all planned chemotherapy cycles have been delivered and until the end of the study at 18 months after the last dose of chemotherapy. Patients with symptomatic progression in the bone may be unblinded and crossed over to denosumab (if on placebo). All participants will be provided with 1000 mg of calcium and 400 IU of vitamin D to be taken daily. Participants who discontinue the investigational product early will be followed for disease status and survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: December 1, 2020
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed urothelial carcinoma (kidney, ureter, bladder) with metastatic disease involving the bones, not amenable to curative treatment

• Mixed histologies permitted as long as urothelial histology is the major component Presence of one or more bone metastases

• No prior systemic chemotherapy for metastatic disease (immunotherapy permitted)

• Starting first line chemotherapy for metastatic urothelial cancer with gemcitabine and cisplatin or gemcitabine and carboplatin and planned to receive 4-6 cycles

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Adequate renal function

• Acceptable serum calcium or albumin-adjusted serum calcium

• Adequate hepatic function

• Patients all require oral examination and appropriate preventative dentistry prior to starting treatment

• Expected life expectancy of at least 3 months

Exclusion Criteria:

• Prior chemotherapy for metastatic disease

• Current or prior IV bisphosphonate or denosumab administration

• Current or prior oral bisphosphonate administration to treat bone metastases

• Unacceptable renal function

• Abnormal bone metabolism (Paget's disease)

• Untreated or symptomatic brain metastases

• Patients with a history of other malignancies, with exceptions

• Significant dental/oral disease

• Administration of other prior anticancer therapies within 2 weeks of randomization

• Patient is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment

• Female of child bearing potential is not willing to use, in combination with her partner, highly effective contraception during treatment and for 7 months after the end of treatment

• Known sensitivity to any of the products to be administered during the study

• History of any other clinically significant disorder, condition or disease that in the opinion of the investigator excludes the patient

Related Conditions & MeSH terms

• Bladder Cancer
• Kidney Cancer
• Kidney Neoplasms
• Ureter Cancer
• Ureteral Neoplasms
• Urothelial Carcinoma

Intervention

Drug:
• Denosumab
RANK Ligand Inhibitor

Other:
• Denosumab Placebo
Placebo

Drug:
• Gemcitabine
Antineoplastic Agent
• Carboplatin
Antineoplastic Agent
• Cisplatin
Antineoplastic Agent

Dietary Supplement:
• Calcium
Calcium Supplement
• Vitamin D
Vitamin D Supplement

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Amgen

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in mean percentage change in serum c-telopeptide (sCTX) between the two arms (investigational drug arm and placebo arm).	Mean percentage change should be greater than or equal to 30%.	Baseline to Week 10
Secondary	Number of patients with a change in sCTx	To determine the proportion of patients with a change in sCTx of >30% from baseline at week 1 to week 10	Baseline to Week 10
Secondary	Mean percentage change in serum bone-specific alkaline phosphatase (bALP) in the investigational arm		Baseline to Week 10
Secondary	Mean percentage change in urinary N-telopeptide (uNTx) levels in the investigational arm		Baseline to Week 10
Secondary	Mean percentage change in sCTx levels in the investigational arm		Baseline to End of Chemotherapy (Week 20)
Secondary	Mean percentage change in bALP levels in the investigational arm		Baseline to End of Chemotherapy (Week 20)
Secondary	Mean percentage change in uNTx levels in the investigational arm		Baseline to End of Chemotherapy (Week 20)
Secondary	Mean percentage change in serum bone-specific alkaline phosphatase (bALP) in the placebo arm.		Baseline to Week 10
Secondary	Mean percentage change in urinary N-telopeptide (uNTx) levels in the placebo arm.		Baseline to Week 10
Secondary	Mean percentage change in sCTx levels in the levels in the placebo arm.		Baseline to End of Chemotherapy (Week 20)
Secondary	Mean percentage change in bALP levels in the levels in the placebo arm.		Baseline to End of Chemotherapy (Week 20)
Secondary	Mean percentage change in uNTx levels in the levels in the placebo arm.		Baseline to End of Chemotherapy (Week 20)
Secondary	Time to first on study symptomatic skeletal related events	To determine and compare the time to first on study symptomatic skeletal related events (SSE); (fracture, surgery, radiation to bone, or spinal cord compression) between each arm of the study	2 years
Secondary	Progression free survival rate	To determine progression free survival (PFS) in each arm at 1 year (with appropriate censoring) after last dose of chemotherapy	1 year
Secondary	Progression free survival rate	To determine progression free survival (PFS) in each arm at 18 months (with appropriate censoring) after last dose of chemotherapy	18 months
Secondary	Overall survival rate	To determine overall survival (OS) rate at 1 year (with appropriate censoring) after last dose of chemotherapy	1 year
Secondary	Overall survival rate	To determine overall survival (OS) rate at 18 months (with appropriate censoring) after last dose of chemotherapy	18 months
Secondary	Number of participants with side effects in the investigational drug arm	To evaluate safety and tolerability	2 years
Secondary	Number of participants with side effects in the placebo arm	To evaluate safety and tolerability	2 years